Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: CuttingEdge Bio who wrote (3384)	10/5/2021 9:07:52 PM
From: BioBait	Read Replies (2) \| Respond to of 3557

Yes, I assume the 1.4 m inventory will be all gone early next year. Then another order to refill 1m+ In 2022. But after that who knows. All other orders would be a bonus. I still think there will be lots of variants and reinfection in 2022+. But, analysts probably won’t factor in revenue for 2023 for COV2. Plus discount for eylea coming off patent. I don’t believe it but Analysts do. So 2 negatives. 2 positive dupy and oncology. Guess we will need to wait for 2023 to find out if rev/earning continue to increase. 2022 should be another good year. Jmho. I’m Probably wrong.